Bibliography
- Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. The GOLD Workshop Report (updated 2007). Available from: www.goldcopd.com (October 2008)
- Antoniu SA, Mihaescu T, Donner CF. Inhaled therapy for stable chronic obstructive pulmonary disease. Expert Opin Pharmacother 2007;8(6):777-85
- Antoniu S, Donner CF. Fluticasone propionate in COPD airway inflammation: there is a partial effect? Expert Rev Pharmacoecon Outcomes Res 2002;2(5):415-7
- Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89
- Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177(11):1207-14
- Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002;165(12):1592-6
- Gizycki MJ, Hattotuwa KL, Barnes N, et al. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 2002;57(9):799-803
- Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173(7):736-43
- Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170(7):760-5